Skip to content

Rheum@Home: RA Remote Patient Monitoring

Rheum@Home: Rheumatoid Arthritis Care in the 21th Century

Status
Withdrawn
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05725577
Acronym
R@H
Enrollment
0
Registered
2023-02-13
Start date
2023-06-01
Completion date
2023-06-01
Last updated
2024-11-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rheumatoid Arthritis

Brief summary

The goal of this pragmatic multicentre clinical trial is to investigate whether telemonitoring with Rheum@Home leads to less outpatient visits, while maintaining tight disease control and high patient-experienced quality of care in patients with rheumatoid arthritis. Participants will be asked to * complete questionaires every 4 weeks * perform a walking test every 4 weeks * routine lab * routine disease activity measurement by a qualified assessor Researchers will compare care via the telemedicine system (intervention) or standard care (control) to see if there are differences in the number of rheumatology outpatient visits and patient reported quality of care after 12 months follow up.

Interventions

OTHERcare via the telemedicine system

Care via the telemedicine system

OTHERRoutine care

Routine care

Sponsors

University of Twente
CollaboratorOTHER
Reade Rheumatology Research Institute
CollaboratorOTHER
Maastricht University Medical Center
CollaboratorOTHER
Medisch Spectrum Twente
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No

Inclusion criteria

* all consecutive patients; * signed, written informed consent; * 18 -75 years of age; * clinical diagnosis of RA; * ≥ 6 months stable low disease activity or remission, according to the treating rheumatologist; * able to read and understand simple Dutch language instructions; * ownership or access to a smartphone, tablet or computer and having internet access; * able to conduct a teleconsultation on a smartphone, tablet or computer.

Exclusion criteria

* severe comorbidity or other factors necessitating continuation of regular outpatient visits, according to the treating rheumatologist

Design outcomes

Primary

MeasureTime frameDescription
Number of rheumatology outpatient visits with rheumatologists and nurses12 month periodNumber of rheumatology outpatient visits with rheumatologists and nurses
Patient-reported quality of care12 month periodmeasured with visual analogue scale (VAS) scores (0-10; higher score indicates higher quality) in seven relevant domains: patients' satisfaction with health care, patients' experiences contacting their health-care providers, the extent to which health care meets patients' expectations, healthcare workers' timeliness of response to questions and symptoms, health-care workers' fulfilment of agreements, health-care workers attentiveness to acute situations, and hospital accessibility in case of symptoms. A mean score of 8 out of 10 or higher was predefined as perceived high quality

Secondary

MeasureTime frameDescription
PROMs: disease activity score (RAPID3)12 month periodPROMs: disease activity score (RAPID3)
PROMs: Patient acceptable symptom state (PASS)12 month periodPROMs: Patient acceptable symptom state (PASS)
Number of rheumatology teleconsultations (email, telephone, video)12 month periodNumber of rheumatology teleconsultations (email, telephone, video)
DAS2812 month periodDisease Activity Score
PROMs: participation (WPAI)12 month periodPROMs: participation (WPAI)
PROMs: pain (NRS)12 month periodPROMs: pain (NRS)
PROMs: fatigue (NRS)12 month periodPROMs: fatigue (NRS)
PROMs: physical function (HAQ-DI)12 month periodPROMs: physical function (HAQ-DI)
PROMs: health related quality of life (EQ5D)12 month periodPROMs: health related quality of life (EQ5D)
PROMs: health related quality of life (SF36)12 month periodPROMs: health related quality of life (SF36)
Physical performance: 50 meter walking test12 month periodPhysical performance: 50 meter walking test
Number of participants with treatment-related adverse events as assessed by CTCAE v4.012 month period(S)AE's assessed by CTCAE v4.0
Cost-effectiveness: healthcare utilization questionnaire12 month periodCost-effectiveness: healthcare utilization questionnaire
Patient experience: System usability scale (SUS)12 month periodPatient experience: System usability scale (SUS)
Patient experience: Perceived efficacy in patient-physician interactions (PEPPI-5)12 month periodPatient experience: Perceived efficacy in patient-physician interactions (PEPPI-5)

Countries

Netherlands

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026